BioNotebook: Argos takes another stab at IPO, Third Rock-backed Eleven also files for offering
This article was originally published in Scrip
After scrapping its plans for an initial public offering in early 2012, Argos Therapeutics is going to try again. Eleven Biotherapeutics, a company backed by Third Rock Ventures, also plans to go public.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.